Janssen’s first AAV programs remain in play with AAO readouts

Janssen’s entrance into gene therapies through retinal diseases remains on track, with new data from its X-linked retinitis pigmentosa and geographic atrophy candidates supporting moves into later-stage clinical trials. 

At the American Association of Ophthalmology (AAO) 2022 annual meeting on Saturday, the Janssen Pharmaceuticals Inc. unit of Johnson & Johnson (NYSE:JNJ) reported that a pair of gene therapies for retinal diseases met the primary safety endpoints in Phase I and I/II studies, and showed early evidence of efficacy. ...